相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Health care costs related to home spirometry in the eICE randomized trial
Natalie Franz et al.
JOURNAL OF CYSTIC FIBROSIS (2022)
Ototoxicity in cystic fibrosis patients receiving intravenous tobramycin for acute pulmonary exacerbation * Ototoxicity following tobramycin treatment
E. Emily Harruff et al.
JOURNAL OF CYSTIC FIBROSIS (2021)
Correspondence between symptoms and preference-based health status measures in the STOP study
Laura S. Gold et al.
JOURNAL OF CYSTIC FIBROSIS (2019)
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial
Harry G. M. Heijerman et al.
LANCET (2019)
Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele
P. G. Middleton et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Acute Pulmonary Exacerbations in Cystic Fibrosis
Christopher H. Goss
SEMINARS IN RESPIRATORY AND CRITICAL CARE MEDICINE (2019)
Caregiver Burden Due to Pulmonary Exacerbations in Patients with Cystic Fibrosis
Ellison Suthoff et al.
JOURNAL OF PEDIATRICS (2019)
Vitamin D for the Immune System in Cystic Fibrosis (DISC): a double-blind, multicenter, randomized, placebo-controlled clinical trial
Vin Tangpricha et al.
AMERICAN JOURNAL OF CLINICAL NUTRITION (2019)
The top 10 research priorities in cystic fibrosis developed by a partnership between people with CF and healthcare providers
Nicola J. Rowbotham et al.
THORAX (2018)
Study design considerations for the Standardized Treatment of Pulmonary Exacerbations 2 (STOP2): A trial to compare intravenous antibiotic treatment durations in CF
Sonya L. Heltshe et al.
CONTEMPORARY CLINICAL TRIALS (2018)
Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D-CFTR mutation treated with ivacaftor
Patrick A. Flume et al.
JOURNAL OF CYSTIC FIBROSIS (2018)
Negative hearing effects of a single course of IV aminoglycoside therapy in cystic fibrosis patients
Malcolm A. Gleser et al.
INTERNATIONAL JOURNAL OF AUDIOLOGY (2018)
A first step to STOP cystic fibrosis exacerbation
Pierre-Regis Burgel et al.
JOURNAL OF CYSTIC FIBROSIS (2017)
Standardized Treatment of Pulmonary Exacerbations (STOP) study: Observations at the initiation of intravenous antibiotics for cystic fibrosis pulmonary exacerbations
Don B. Sanders et al.
JOURNAL OF CYSTIC FIBROSIS (2017)
Standardized Treatment of Pulmonary Exacerbations (STOP) study: Physician treatment practices and outcomes for individuals with cystic fibrosis with pulmonary Exacerbations
Natalie E. West et al.
JOURNAL OF CYSTIC FIBROSIS (2017)
Rationalizing endpoints for prospective studies of pulmonary exacerbation treatment response in cystic fibrosis
D. R. VanDevanter et al.
JOURNAL OF CYSTIC FIBROSIS (2017)
Challenges in the Design and Interpretation of Noninferiority Trials
Laura Mauri et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Estimating Direct Cost of Cystic Fibrosis Care Using Irish Registry Healthcare Resource Utilisation Data, 2008-2012
Abaigeal D. Jackson et al.
PHARMACOECONOMICS (2017)
Home Monitoring of Patients with Cystic Fibrosis to Identify and Treat Acute Pulmonary Exacerbations eICE Study Results
Noah Lechtzin et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2017)
Short-term and long-term response to pulmonary exacerbation treatment in cystic fibrosis
Sonya L. Heltshe et al.
THORAX (2016)
IV-treated pulmonary exacerbations in the prior year: An important independent risk factor for future pulmonary exacerbation in cystic fibrosis
Donald R. VanDevanter et al.
JOURNAL OF CYSTIC FIBROSIS (2016)
Probability of IV antibiotic retreatment within thirty days is associated with duration and location of IV antibiotic treatment for pulmonary exacerbation in cystic fibrosis
D. R. VanDevanter et al.
JOURNAL OF CYSTIC FIBROSIS (2016)
Duration of Antibiotic Treatment in Community-Acquired Pneumonia A Multicenter Randomized Clinical Trial
Ane Uranga et al.
JAMA INTERNAL MEDICINE (2016)
The Cystic Fibrosis Foundation Patient Registry Design and Methods of a National Observational Disease Registry
Emily A. Knapp et al.
ANNALS OF THE AMERICAN THORACIC SOCIETY (2016)
Cystic fibrosis
Felix Ratjen et al.
NATURE REVIEWS DISEASE PRIMERS (2015)
Update in Cystic Fibrosis 2013
Manu Jain et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2014)
Longevity of Patients With Cystic Fibrosis in 2000 to 2010 and Beyond: Survival Analysis of the Cystic Fibrosis Foundation Patient Registry
Todd MacKenzie et al.
ANNALS OF INTERNAL MEDICINE (2014)
Weakly acidic gastroesophageal refluxes are frequently triggers in young children with chronic cough
Michele Ghezzi et al.
PEDIATRIC PULMONOLOGY (2013)
Effect of pulmonary exacerbations on long-term lung function decline in cystic fibrosis
Valerie Waters et al.
EUROPEAN RESPIRATORY JOURNAL (2012)
Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations
Philip H. Quanjer et al.
EUROPEAN RESPIRATORY JOURNAL (2012)
Early-Onset Ventilator-Associated Pneumonia in Adults Randomized Clinical Trial: Comparison of 8 versus 15 Days of Antibiotic Treatment
Gilles Capellier et al.
PLOS ONE (2012)
Risk Factors for Chronic Kidney Disease in Adults with Cystic Fibrosis
Bradley S. Quon et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2011)
Exacerbation frequency and clinical outcomes in adult patients with cystic fibrosis
Kaissa de Boer et al.
THORAX (2011)
Failure to Recover to Baseline Pulmonary Function after Cystic Fibrosis Pulmonary Exacerbation
Don B. Sanders et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2010)
Comparison of 7-day and repeated 24-hour recall of symptoms of cystic fibrosis
Antonia V. Bennett et al.
JOURNAL OF CYSTIC FIBROSIS (2010)
A comparison of the results of intent-to-treat, per-protocol, and g-estimation in the presence of non-random treatment changes in a time-to-event non-inferiority trial
Yutaka Matsuyama
STATISTICS IN MEDICINE (2010)
Cystic Fibrosis Pulmonary Guidelines Treatment of Pulmonary Exacerbations
Patrick A. Flume et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2009)
Risk factors for rate of decline in forced expiratory volume in one second in children and adolescents with cystic fibrosis
Michael W. Konstan et al.
JOURNAL OF PEDIATRICS (2007)
The role of intention to treat in analysis of noninferiority studies
Brian L. Wiens et al.
CLINICAL TRIALS (2007)
Effectiveness of early switch from intravenous to oral antibiotics in severe community acquired pneumonia: multicentre randomised trial
Jan Jelrik Oosterheert et al.
BMJ-BRITISH MEDICAL JOURNAL (2006)
Choosing the analysis population in non-inferiority studies: Per protocol or intent-to-treat
MM Sanchez et al.
STATISTICS IN MEDICINE (2006)
General considerations for lung function testing
MR Miller et al.
EUROPEAN RESPIRATORY JOURNAL (2005)
Comparison of 8 vs 15 days of antibiotic therapy for ventilator-associated pneumonia in adults - A randomized trial
J Chastre et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
Impact of recent pulmonary exacerbations on quality of life in patients with cystic fibrosis
MT Britto et al.
CHEST (2002)
Predictive 5-year survivorship model of cystic fibrosis
TG Liou et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2001)
分享论文
